Background {#Sec1}
==========

Rett syndrome (RTT; OMIM Entry \#312750) is a neurodevelopmental disorder which is one of the main causes of neurological disability in children \[[@CR1]\]. Rett syndrome almost occurs in females, the estimate incident of RTT worldwide is 1:10.000--1:15000 female births \[[@CR2]\]. The classic clinical presentation of RTT is characterized by average psychomotor progression from birth until 6--18 months, and then development halted followed by period of psychomotor deterioration \[[@CR3], [@CR4]\] . During the phase of deterioration, the patients often present stereotypic movements (classic RTT hand), loss of acquired motor skills and communication skills \[[@CR5]\]. The neurodevelopmental of the child may stabilize or in some case, limited recovery can be observed in the next phase called the pseudo-stationary stage \[[@CR6]\]. Other complications and symptoms of RTT may include seizure, cardiac abnormalities, irregular breathing patterns and scoliosis \[[@CR7]--[@CR9]\]. The level of motor impairment becomes more severe as the child's age \[[@CR10]\]. There are also atypical RTT patients whom present with several but not all clinical features and progression phases of classical RTT \[[@CR11]\].

The most common cause of RTT is de novo mutations in the MECP2 gene (Methyl-CpG binding protein 2), located on the X chromosome (locus Xq28) \[[@CR1]\]. Additionally, the gene is also subjected to X-chromosome inactivation, which alters the severity and manifestation of RTT \[[@CR12]\]. The MECP2 gene consists of four exons and encode for the widely expressed methyl-CpG-binding protein 2 -- member of the methyl-binding domain protein family. MECP2 is an important transcription factor, which functions by interaction and modification of epigenetic factors \[[@CR13]\]. There exist two isoforms of MECP2 (MeCP2_e1 and MeCP2_e2) which have slight difference in their expression levels between tissues and distinct N termini. MeCP2_e1 is most commonly found in the brain tissue whilst MeCP2_e2 predominate in the placenta, liver and skeletal muscle tissues \[[@CR14], [@CR15]\]. Many studies have addressed MECP2 role in RTT, beside the critical role in neurodevelopmental process, MECP2 have been hypothesized to help maintenance of synaptic function, brain cell connectivity and neuronal plasticity \[[@CR16], [@CR17]\].

To date, around 1000 disease-causing MECP2 mutations have been characterized and recorded in multiple databases such as RettBASE and The Human Gene Mutation Database \[[@CR18]\]. Case reports of asymptomatic carriers or carriers with mild clinical symptoms have been found to have skewed X chromosome inactivation (XCI) in preference of the normal copy of MECP2 \[[@CR12]\]. In addition, MECP2 mutations have been loosely associated with other pediatric neurological conditions, most notably autism, Angelman syndrome, and many behavioral and intellectual disorders \[[@CR19], [@CR20]\].

In Vietnam, the lack of awareness and knowledge is also a major problem as consultation measures need to be provided families of RTT patients. Diagnosis of RTT require both clinical and molecular evidence, in which characterization of MECP2 gene is required for the disorder and provide valuable information for clinician in planning care and treatments.

In this study we first report the mutation spectrum of MECP2 in Vietnamese patients with clinically diagnosed for Rett syndrome, in which 4 novel mutations was found. This finding is an important step toward understanding and development of therapy to help patients suffering from RTT.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

The study assessed 27 female patients presented with sporadic, RTT phenotype; diagnosis were made based on the criteria by Neul et al. \[[@CR11]\]. Specialized pediatricians and neurologists at Vinmec hospital made clinical evaluation and confirmation of RTT. The Ethical board of Vinmec International Hospital approved of the study; informed consent was obtained from the parents of the patients.

Inclusion criteria {#Sec4}
------------------

Female patients were recruited in the study based on classic presentation of RETT syndrome: average psychomotor progression from birth until 6--18 months of age, with no history of brain injury, trauma or serious infection. The patients presented with 2 out of 4 main clinical criteria:Loss of acquired hand skillsLoss of acquired language skillGait abnormalities: impaired (dyspraxic) or absence of abilityStereotypic hand movements

Molecular analysis {#Sec5}
------------------

The genomic DNA was extracted from patient's peripheral blood using the Wizard® Genomic DNA Purification Kit (Promega). The DNA quality was tested by the NanoDrop spectrophotometer. In order to perform mutant analysis, we designed primers to amplify the complete coding region (exon 2, 3, 4) including flanking intronic splice site sequence and 5'UTR within exon 2 and 3'UTR based on published genomic sequence of MECP2.

DNA was amplified by manual PCR method using GoTaq® Green Master Mix (Promega) on the GeneAmp PCR system 9700 thermocycler. The PCR product was checked on agarose gel and purified using QIAquick PCR purification Kit (Qiagen) according to the manufacturer's instruction. The purified PCR product was sequenced directly in both strands using the BigDye® Terminator v3.1 Cycle Sequencing Kit (Thermo Fisher Scientific) by automated fluorescent sequencing technology (Applied Biosystems 3500 Dx Genetic Analyzer). We used DNAstar to compare the patients' MECP2 sequences with the reference MECP2 sequence (Genebank accession number. MECP2 locus, AF030876; MECP2, ENSG00000169057). The novel mutation was confirmed by doing extensive search on RettBASE and The Human Gene Mutation Database as well as from prior publications. We used in silico analysis to predict the consequence of the mutation identified in our cohort. The tool used were Polyphen-2 \[[@CR21]\] and MutationTaster \[[@CR22]\].

Results {#Sec6}
=======

Mutation analysis of the MECP2 gene {#Sec7}
-----------------------------------

Mutation analysis was conducted in 27 female patients. The diagnosis followed the standard protocol: After clinical evaluation, blood sample was taken and PCR with the designated primers (Table [1](#Tab1){ref-type="table"}) was used to amplify MECP2, followed by Sanger sequencing of the exons and compare with reference sequence to detect mutations. On clinical examination, all patients presented with history of a period of neurodevelopmental regression followed by recovery or stabilization, together with partial or complete loss of motor and language skill and stereotypic hand movements.

Mutation analysis detected MECP2 mutation in 20 out of 27 patients (mutation detection rate 74%)(Table [2](#Tab2){ref-type="table"}). The study identified 14 pathogenic mutations, including 2 missenses, 4 nonsenses, 6 frame shifts and 2 deletions. The mutations that occur more frequently were c.473 C \> T (*n* = 4); c.808 C \> T (*n* = 4), c.763 C \> T (*n* = 2) and c.502C \> T (*n* = 2). All mutation were predicted to be disease causing by in silico analysis (Table [3](#Tab3){ref-type="table"}).Table 1Primers used in MECP2 amplificationAmpliconLength (bp)Forward primerReverse primerExon 2355TAGCCCTGGGAAAAAGGTCGGGCACAGTTTGGCACAGTTATExon 3484CCTGCCTCTGCTCACTTGTTCATGAGGGATCCTTGTCCCTGExon 4.1429TGCCCTATCTCTGACATTGCTATGACCTGGGTGGATGTGGTExon 4.2631GTCCTGGGAAGCTCCTTGTCCTCTCCAGTGAGCCTCCTCTExon 4.3388CAGCGTCTGCAAAGAGGAGACCCTGAAGCCACGAAACTCTTable 2Mutation alleles frequency of RETT patientsPatient No.Mutation of *MECP2*Mutation typeNovel mutationNucleotide changeAmino acid change1--4c.473C \> Tp.T158 MMissenseNo5--8c.808C \> Tp. R270XNonsenseNo9--10c.763C \> Tp.R255XNonsenseNo11--12c.502C \> T,p. R168XNonsenseNo13c.1384-1385del GTV462fsFrameshiftYes14c.763C \> Tp.R255XNonsenseNoc.1205insTp.P402LfsFrameshiftYes15Exon 4 deletion_Large deletionNo16c.(164--182)del 19p.Q56fsFrameshiftNo(1148--1193)del 46p.L383fsFrameshiftNo17c.717del Cp.A240fsFrameshiftYes18c.806del Gp. G269fsFrameshiftNo19c.1132_1207del77A378fsDeletionYes20c.917G \> Ap.R306HMissenseNoTable 3In silico analysis to determine the causal relationship of the mutation and RETT syndromeNucleotide changeAmino acid changeDomainMutationTasterPolyPhen-2Referencec.473C \> Tp.T158 MMDBDisease causingProbably damaging with a score of 1.000Rettbasec.808C \> Tp. R270XTRD-NLSDisease causingN/ARettbasec.763C \> Tp.R255XTRDDisease causingN/ARettbasec.502C \> T,p. R168XInter-domain regionDisease causingN/ARettbasec.1384-1385del GTp.V462fsC- termDisease causingN/ANovelc.763C \> Tp.R255XTRDDisease causingN/ARettbasec.1205insTp.402LfsC - termDisease causingN/ANovelc.(164--182)del 19p.Q56fsTRD-NLS, 3'UTRDisease causingN/ARettbasec.(1148--1193)del 46p.L383fsC - termDisease causingN/ARettbasec.717delCp.A240fsTRDDisease causingN/ANovelc.806delGp. G269fsTRD-NLSDisease causingN/ARettbasec.1132_1207del77A378fsC -- termDisease causingN/ANovelc.917G \> Ap.R306HTRDDisease causingProbably damaging with a score of 0.999RettbaseN/A: Not applicable

A novel mutation was also identified: c.1384--1385 del GT (Fig. [1](#Fig1){ref-type="fig"}), a two-nucleotide deletion which lead to frameshift and alter the amino-acid sequence and premature termination of the protein product. The carrier was a female patient diagnosed with classic RTT at the age of 3. We also identified 3 other novel mutations: c.1205insT, c.717delC and c.1132_1207del77, to the best of our knowledge, not described in the MECP2 mutation database (Rettbase) or previously described in any publication.Fig. 1Sanger sequencing result of the patient with novel mutation (c.1384--1385 del GT)

In silico prediction of mutation {#Sec8}
--------------------------------

Two in silico tool (Polyphen-2, MutationTaster) were used to predict the consequence of mutation. We identified the region change, probability of disease causing and potential changes to protein structure of each mutation identified in our cohort.

Discussion {#Sec9}
==========

The current study investigated the mutation spectrum of MECP2 in Vietnamese patients. The patients had been enrolled and pediatricians and neurologists carried out clinical evaluation. Therefore, the cohort is well defined and well suited for molecular study. Prior to availability of MECP2 mutation test, criteria for Rett syndrome diagnosis are based on a collection of clinical features organized into age-related stages \[[@CR23]\]. Classic Rett syndrome was classified for girls meeting all main criteria while variants of this disorder were marked for patients with a less severe clinical presentation, including preserved speech or hand use, normal head circumference, or delayed symptom onset.

Mutations of MECP2 gene are highly correlated with RTT and have been found in other neurological disorder such as autism, Angelman syndrome, and other behavioral and intellectual disorders. Therefor molecular diagnosis for MECP2 mutations is an important step in diagnosis of neurodevelopmental disorders. Routine diagnostic protocol for MECP2 mutations is often carried out by DNA sequencing because of the gene's broad spectrum of mutation.

We identified MECP2 mutation in 74% of the cases, the mutation detection rate is comparable with other study in which MECP2 mutations were identified in approximately 75% of RTT patients \[[@CR24]--[@CR26]\] . The result suggest that MECP2 mutation is not the only cause of RTT, as there are also FOXG1 gene (locus 14q13) which causes the congenital variant of Rett syndrome and others mutations which could also lead to RTT \[[@CR27]\]. Furthermore, we did not take into account intronic sequence change (i.e. splice site mutation) which could lead to changes in the protein structure and function. Therefore, the absent of MECP2 alone is not enough to rule out the possibility of RTT in cases where the child does not have typical symptoms or not old enough to conclude with the diagnosis of classic RTT.

The study identified 14 pathogenic mutations, including 2 missenses, 4 nonsenses, 6 frame shifts and 2 deletions. The more frequently detected mutations in our cohort (c.473 C \> T; c.808 C \> T, c.763 C \> T and c.502C \> T) are also the most common mutations reported worldwide as listed on RettBASE \[[@CR18]\]. The mutation profile suggested that the similarity of the mutation spectrum in MECP2 is not the product of heredity, but the susceptibility of the mutation sites. We noted that most of the point mutations in our cohort are C \> T in CpG sites. The CpG sites are often mutation hotspot because the cytosine in these sites is often methylated (mCpG) and 5-methylcytosine is genetically unstable \[[@CR28]\]. In disorder like RTT, which is strictly due to de novo mutations, these CpG sites mutations became more frequent.

In our cohort, we detected a novel mutation not listed previously in any mutation databases: c.1384-1385delGT. The patient had clear clinical presentations of classic RTT. The patients had a relatively normal neurodevelopmental phase in the first 8 months, and then the child's development regressed. At 12 months of age, she experienced a seizure and was taken to the hospital. At 3 years of age, she was unable to walk independently, and stereotypic hand movements hindered hand usage. She exhibited poor interaction to her surrounding and to other people, and show no communication ability. In silico analysis confirmed the mutation as a disease causing variant.

Before the availability of MECP2 mutation test in Vietnam, criteria for the diagnosis of Rett were solely based on clinical findings. This could lead to the under-diagnosis of Rett thus, overlooking the milder form of the disease. In order to better manage and reduce the incident of Rett we need to develop a framework to provide counseling, prenatal diagnosis for the patients and families.

Conclusions {#Sec10}
===========

In conclusion, the study has identified and characterized a spectrum of MECP2 mutations in sporadic case of Rett syndrome and patients with Rett like feature. Because of the clinical consequence and also the lack of data of Rett syndrome in Vietnam, future studies need to be conducted on a larger scale in different parts of the country and could provide better counseling for the patients as well as their families. The mutation spectrum of Vietnamese patients will also contribute to the global mutations database and help progress toward better understanding the etiology of the disorder and aid treatment in the near future.
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